[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 19 of about 19
1. Mladenović-Segedi L: [Primary fallopian tube carcinoma]. Med Pregl; 2009 Jan-Feb;62(1-2):31-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary fallopian tube carcinoma].
  • INTRODUCTION: Primary fallopian tube carcinoma is extremely rare, making 0.3-1.6% of all female genital tract malignancies.
  • CLINICAL FEATURES: The most prevailing symptoms with fallopian tube carcinoma are abdominal pain, abnormal vaginal discharge/bleeding and the most common finding is an adnexal mass.
  • In many patients, fallopian tube carcinoma is asymptomatic.
  • DIAGNOSIS: Due to its rarity, preoperative diagnosis of primary fallopian tube carcinoma is rarely made.
  • It is usually misdiagnosed as ovarian carcinoma, tuboovarian abscess or ectopic pregnancy.
  • Sonographic features of the tumor are non-specific and include the presence of a fluid-filled adnexal structure with a significant solid component, a sausage-shaped mass, a cystic mass with papillary projections within, a cystic mass with cog wheel appearance and an ovoid-shaped structure containing an incomplete separation and a highly vascular solid nodule.
  • More than 80% of patients have elevated pretreatment serum CA-125 levels, which is useful in follow-up after the definite treatment.
  • TREATMENT: The treatment approach is similar to that of ovarian carcinoma, and includes total abdominal hysterectomy and bilateral salpingo-oophorectomy.
  • Staging is followed with chemotherapy.
  • [MeSH-major] Carcinoma. Fallopian Tube Neoplasms

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19514598.001).
  • [ISSN] 0025-8105
  • [Journal-full-title] Medicinski pregled
  • [ISO-abbreviation] Med. Pregl.
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Serbia
  • [Number-of-references] 51
  •  go-up   go-down


2. Yu AJ, Fang SH, Gao YL: [Analysis of therapeutic result and prognostic factor in primary fallopian tube carcinoma]. Zhonghua Zhong Liu Za Zhi; 2007 Oct;29(10):789-93
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of therapeutic result and prognostic factor in primary fallopian tube carcinoma].
  • OBJECTIVE: To investigate the impact of treatment modality and clinicopathologic profile on prognosis in primary fallopian tube carcinoma.
  • METHODS: The data of 64 cases with primary fallopian tube carcinoma treated between January 1991 and June 2006 were analyzed.
  • However, there was no significant difference in 3-year and 5-year survival rate between the group with pelvic lymphadenectomy and the group without (84.2% vs. 69.2%, P = 0.4667; 63.1% vs. 53.8%, P = 0.459), and also between the group treated using CAP/CP regimen and the group by TP regimen for chemotherapy (81.8% vs. 80.0%, P = 0.8946; 59.1% vs. 60.0% P = 0.9582).
  • It was found that the 5-year survival was correlated with FIGO stage (III-IV vs. I - II, P = 0.0197), differentiation grade (G3 vs. G1 + G2, P = 0.003), pathologic type (other type vs. serous, P = 0.0494), lymph nodes status (positive vs. negative, P = 0.0295).
  • CONCLUSION: Surgical staging, optimal cytoreduction, differentiation grade, pathologic type, lymph node status are important factors influencing the 5-year survival in primary fallopian tube carcinoma.
  • Pelvic lymphadenectomy is necessary and feasible to perform during the procedure of surgical staging and cytoreduction.
  • CAP/CP and TP regiment are similarly effective in adjuvant chemotherapy for primary fallopian tube carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cystadenocarcinoma, Papillary / surgery. Fallopian Tube Neoplasms / surgery. Hysterectomy / methods. Ovariectomy / methods
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Cyclophosphamide / therapeutic use. Female. Follow-Up Studies. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Survival Rate. Taxoids / therapeutic use

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18396696.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Taxoids; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; CP protocol; TP protocol
  •  go-up   go-down


3. Khan Y, Haq AN, Nasar R: Primary fallopian tube carcinoma presenting with a sinus in the posterior portion of cervix. Int J Gynecol Cancer; 2004 Jan-Feb;14(1):166-8
MedlinePlus Health Information. consumer health - Fistulas.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary fallopian tube carcinoma presenting with a sinus in the posterior portion of cervix.
  • Primary fallopian tube carcinoma is an aggressive but rare tumor.
  • This is an unusual presentation of papilliferous tubal carcinoma presenting with vaginal discharge through a large sinus approximately 2-3 cm in size, located posterior to the neck of cervix.
  • Surgery was undertaken with the initial diagnosis of primary ovarian carcinoma and the fistula was left to heal spontaneously.
  • Surgical resection was followed by adjuvant chemotherapy.
  • The patient is doing well after the therapy.
  • [MeSH-major] Adenocarcinoma, Papillary / diagnosis. Fallopian Tube Neoplasms / diagnosis. Fistula / diagnosis. Uterine Cervical Diseases / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Cervix Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14764047.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Villella J, Marchetti D, Odunsi K, Rodabaugh K, Driscoll DL, Lele S: Response of combination platinum and gemcitabine chemotherapy for recurrent epithelial ovarian carcinoma. Gynecol Oncol; 2004 Dec;95(3):539-45
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response of combination platinum and gemcitabine chemotherapy for recurrent epithelial ovarian carcinoma.
  • METHODS: Retrospective chart review of all patients with recurrent, persistent, or progressive fallopian tube or ovarian carcinoma treated with a platinum-based compound and gemcitabine from 2001 to present was performed.
  • RESULTS: Twenty-nine patients on second to eight line chemotherapy met inclusion criteria.
  • Nineteen of 29 patients (66%) showed platinum resistance to initial therapy.
  • CONCLUSIONS: Adjuvant combination platinum-based agent with gemcitabine is a very effective and well-tolerated treatment for recurrent fallopian tube or ovarian carcinoma; even in those who exhibit initial platinum resistance.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Carboplatin / adverse effects. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cystadenocarcinoma, Papillary / drug therapy. Cystadenocarcinoma, Serous / drug therapy. Drug Synergism. Female. Humans. Middle Aged. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15581960.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


5. Fukunaga M, Fujiwara Y, Naito Z: Hepatoid carcinoma with serous component of the fallopian tube: a case report with immunohistochemical and ultrastructural studies. Int J Gynecol Pathol; 2006 Jul;25(3):233-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatoid carcinoma with serous component of the fallopian tube: a case report with immunohistochemical and ultrastructural studies.
  • A very rare case of hepatoid carcinoma with serous component arising in the fallopian tube of a 79-year-old woman is presented.
  • The tumor was composed of hepatoid carcinoma (90%) and serous carcinoma (10%) components.
  • The hepatoid carcinoma was histologically characterized by a proliferation of round to polygonal cells arranged in a trabecular, tubular, sinusoidal, papillary, or solid pattern.
  • The serous component in the fallopian tube also showed in situ lesions.
  • Immunohistochemically, the hepatoid carcinoma was positive for alpha-fetoprotein, polyclonal carcinoembryonic antigen (CEA), hepatocyte paraffin 1, albumin, epithelial membrane antigen, and cytokeratin (CAM5.2).
  • Ultrastructurally, the cytoplasm contained abundant ribosomes, moderate amounts of mitochondria, and rough endoplasmic reticulum that developed into a meshwork and contained mitochondria within it.
  • The association with serous carcinoma indicates mullerian origin rather than germ cell origin.
  • The patient received chemotherapy and was alive without disease at 10 months after surgery.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Fallopian Tube Neoplasms / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Keratins / analysis. Microscopy, Electron, Transmission. alpha-Fetoproteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16810059.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins; 68238-35-7 / Keratins
  •  go-up   go-down


6. Culton LK, Deavers MT, Silva EG, Liu J, Malpica A: Endometrioid carcinoma simultaneously involving the uterus and the fallopian tube: a clinicopathologic study of 13 cases. Am J Surg Pathol; 2006 Jul;30(7):844-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid carcinoma simultaneously involving the uterus and the fallopian tube: a clinicopathologic study of 13 cases.
  • Although the simultaneous presentation of endometrial and ovarian carcinomas of the endometrioid type is well described, little is known about a similar phenomenon involving the endometrium and fallopian tube (FT).
  • FT tumors that could have represented luminal extension of the endometrial carcinoma or that represented an unequivocal metastasis to the FT were excluded.
  • In 2 cases, there were also small areas of other histologic types, papillary serous carcinoma (1 case), and papillary endometrial carcinoma of intermediate grade (another case).
  • The size of the fallopian tube carcinomas ranged from 0.2 to 17.5 cm.
  • Seven of these tumors were located in the distal/fimbriated end of the FT.
  • The grades of the fallopian tube carcinomas were as follows: Grade 1 (2), Grade 2 (6), and Grade 3 (2).
  • One fallopian tube carcinoma was mixed with serous carcinoma.
  • In 4 cases, there was also an endometrioid carcinoma involving the ovary, all of them with an intact ovarian capsule.
  • Patients were treated as follows: total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAH/BSO) (4), TAH/BSO/chemotherapy (chemo) (4), TAH/BSO/radiation (3), and TAH/BSO/chemo/radiation (2).
  • Follow-up ranging from 6 to 54 months was available in 10 patients: 1 patient died of disease (at 38 mo), 1 patient is alive with disease (at 9 mo), 7 patients have no evidence of disease (6 to 54 mo), and 1 patient died of metastatic endometrial carcinoma (at 9 mo).
  • The FT carcinoma is usually unilateral and located at the distal end of the tube.
  • [MeSH-major] Carcinoma, Endometrioid / secondary. Fallopian Tube Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Fallopian Tubes / pathology. Fallopian Tubes / surgery. Female. Humans. Middle Aged. Neoplasm Staging. Survival Rate

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16819326.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Kuscu E, Oktem M, Haberal A, Erkanli S, Bilezikci B, Demirhan B: Management of advanced-stage primary carcinoma of the fallopian tube: case report and literature review. Eur J Gynaecol Oncol; 2003;24(6):557-60
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of advanced-stage primary carcinoma of the fallopian tube: case report and literature review.
  • Primary carcinoma of the fallopian tube is a very unusual gynecologic malignancy that accounts for less than 1% of all malignancies of the female genitalia.
  • Laparotomy revealed left hydrosalpinx and a papillary-fimbrial mass.
  • The definitive histopathological diagnosis was primary serous adenocarcinoma of the fallopian tube with six of 25 lymph node biopsies showing metastasis.
  • Six cycles of paclitaxel (175 mg/m2) plus cisplatin (75 mg/m2) combinatin chemotherapy were administered with 3-week intervals between cycles.
  • At the time of writing 12 months after the second-look laparotomy, she was still disease-free.
  • [MeSH-major] Cystadenocarcinoma, Serous / diagnosis. Fallopian Tube Neoplasms / diagnosis. Pelvic Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Aorta, Thoracic. Appendectomy. Cisplatin / administration & dosage. Diagnosis, Differential. Fallopian Tubes / surgery. Female. Humans. Hysterectomy. Lymph Nodes / surgery. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Omentum / surgery. Ovariectomy. Paclitaxel / administration & dosage. Second-Look Surgery

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14658603.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 40
  •  go-up   go-down


8. Newton HB, Stevens C, Santi M: Brain metastases from fallopian tube carcinoma responsive to intra-arterial carboplatin and intravenous etoposide: a case report. J Neurooncol; 2001 Dec;55(3):179-84
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastases from fallopian tube carcinoma responsive to intra-arterial carboplatin and intravenous etoposide: a case report.
  • Fallopian tube carcinoma is the least common neoplasm of the female genital tract.
  • It remains unclear, however, what role chemotherapy has in the treatment of these patients and what route of administration is most effective.
  • Intra-arterial (IA) regional administration of chemotherapy may increase intra-tumoral drug concentrations and improve efficacy.
  • We report the case of a 47-year-old woman who developed bilateral fallopian tube cancer and multifocal brain metastases.
  • After progression through radiation therapy and oral chemotherapy, she was placed on IA carboplatin (200 mg/m2/d x 2 days every 4 weeks) and intravenous etoposide (100 mg/m2/d x 2 days every 4 weeks).
  • During treatment she had objective tumor shrinkage that has remained stable for more than 12 months.
  • For patients with fallopian tube carcinoma that develop brain metastases and respond poorly to surgery and/or irradiation, multi-agent chemotherapy containing carboplatin should be considered.
  • [MeSH-major] Adenocarcinoma, Papillary / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / secondary. Brain Stem / pathology. Fallopian Tube Neoplasms / pathology. Temporal Lobe / pathology
  • [MeSH-minor] Antineoplastic Agents, Alkylating / therapeutic use. Carboplatin / administration & dosage. Carotid Arteries. Cisplatin / administration & dosage. Combined Modality Therapy. Cranial Irradiation. Cyclophosphamide / administration & dosage. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Etoposide / administration & dosage. Fallopian Tubes / injuries. Female. Humans. Infusions, Intra-Arterial. Infusions, Intravenous. Magnetic Resonance Imaging. Middle Aged. Paclitaxel / administration & dosage. Physical Examination / adverse effects. Rupture, Spontaneous. Vertebral Artery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Pharmacother. 1999 Jul-Aug;33(7-8):816-32 [10466912.001]
  • [Cites] Oncology (Williston Park). 1989 Oct;3(10):20-6; discussion 26-7, 30, 32 [2701210.001]
  • [Cites] Radiology. 1999 Oct;213(1):135-40 [10540653.001]
  • [Cites] Med Oncol. 1998 Apr;15(1):6-14 [9643524.001]
  • [Cites] Am Fam Physician. 1999 Feb 15;59(4):878-86 [10068711.001]
  • [Cites] J Clin Oncol. 1992 Oct;10(10):1553-60 [1383433.001]
  • [Cites] Expert Opin Investig Drugs. 2000 Dec;9(12):2815-29 [11093355.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):637-47 [10649259.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):71-6 [9422560.001]
  • [Cites] Cancer. 1999 Apr 1;85(7):1599-605 [10193952.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):745-51 [9128946.001]
  • [Cites] Cancer. 1992 Feb 15;69(4):972-80 [1735089.001]
  • [Cites] Neurosurg Clin N Am. 1996 Jul;7(3):527-36 [8823780.001]
  • [Cites] Cancer. 2000 Nov 15;89(10):2076-84 [11066048.001]
  • (PMID = 11859973.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 16058
  • [Publication-type] Case Reports; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; YF1K15M17Y / temozolomide
  •  go-up   go-down


9. Varras M, Akrivis Ch, Bellou A, Malamou-Mitsi VD, Antoniou N, Tolis C, Salamalekis E: Primary fallopian tube adenocarcinoma: preoperative diagnosis, treatment and follow-up. Eur J Gynaecol Oncol; 2004;25(5):640-6
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary fallopian tube adenocarcinoma: preoperative diagnosis, treatment and follow-up.
  • Preoperative diagnosis of fallopian tube carcinoma is difficult due to the rarity and silent course of this neoplasm.
  • We present herein the case of a 58-year-old woman with primary fallopian tube carcinoma that was diagnosed preoperatively on the basis of a positive for adenocarcinoma Papanicolaou vaginal smear, repeated episodes of vaginal bleeding, negative endocervical and endometrial curettage, characteristic features on ultrasonography and elevated CA-125 levels.
  • Pathologic confirmation of primary serous papillary adenocarcinoma of the left fallopian tube was made.
  • FIGO stage was considered as IIIb and the patient received six courses of combined carboplatin-taxol chemotherapy.
  • At two years from onset of therapy the patient underwent a modified radical mastectomy and lymphadenectomy because of primary carcinoma of the right breast.
  • The patient was started on tamoxifen therapy, which she is still taking.
  • In conclusion, our study suggests an association between fallopian tube carcinoma and breast cancer and a good response of the patient to platinum-based chemotherapy.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Cystadenocarcinoma, Papillary / diagnosis. Fallopian Tube Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Estrogen Antagonists / therapeutic use. Female. Humans. Mastectomy. Middle Aged. Neoplasm Staging. Postoperative Period. Preoperative Care. Tamoxifen / therapeutic use

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15493187.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Estrogen Antagonists; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


10. Scholz HS, Lax S, Tamussino KF, Benedicic C, Petru E: Long-term survival of a patient with fallopian tube cancer presenting with a supraclavicular mass. Anticancer Res; 2000 Nov-Dec;20(6C):4801-2
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival of a patient with fallopian tube cancer presenting with a supraclavicular mass.
  • BACKGROUND: Five-year survival of patients with stage IV cancer of the fallopian tube is poor.
  • The mass was removed and histology showed metastatic papillary adenocarcinoma strongly suggestive of papillary serous carcinoma.
  • Abdominal hysterectomy and salpingo-oophorectomy showed a primary carcinoma of the fallopian tube.
  • Postoperatively the patient received six cycles of carboplatin-based chemotherapy and is alive and well with no evidence of disease 5 years and 10 months after the primary diagnosis.
  • CONCLUSION: Surgery and adjuvant carboplatin-based chemotherapy seem justified even in older patients with fallopian tube cancer and distant metastasis at the time of diagnosis.
  • [MeSH-major] Adenocarcinoma, Papillary / drug therapy. Adenocarcinoma, Papillary / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fallopian Tube Neoplasms / drug therapy. Fallopian Tube Neoplasms / surgery
  • [MeSH-minor] Aged. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Clavicle. Cyclophosphamide / administration & dosage. Female. Humans. Hysterectomy. Neoplasm Metastasis. Ovariectomy. Survivors. Time Factors

  • Genetic Alliance. consumer health - Fallopian Tube Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11205221.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


11. Alarab M, Foley M, Fennelly D: Prolonged survival in two cases of carcinoma of the fallopian tube presenting after hysterectomy: case reports. Eur J Gynaecol Oncol; 2003;24(1):91-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged survival in two cases of carcinoma of the fallopian tube presenting after hysterectomy: case reports.
  • Two patients presented with fallopian tube carcinoma after hysterectomy.
  • Both have had a prolonged survival after surgical debulking and chemotherapy with platinum-based agents.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Papillary / surgery. Fallopian Tube Neoplasms / pathology. Fallopian Tube Neoplasms / surgery
  • [MeSH-minor] Biopsy, Needle. Female. Follow-Up Studies. Humans. Hysterectomy / methods. Immunohistochemistry. Middle Aged. Neoplasm Staging. Ovariectomy / methods. Postmenopause. Risk Assessment. Time Factors. Treatment Outcome. Uterine Hemorrhage / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12691329.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


12. Schneider C, Wight E, Perucchini D, Haller U, Fink D: Primary carcinoma of the fallopian tube. A report of 19 cases with literature review. Eur J Gynaecol Oncol; 2000;21(6):578-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary carcinoma of the fallopian tube. A report of 19 cases with literature review.
  • Primary carcinoma of the fallopian tube is the rarest cancer of the female genital tract with an incidence of 0.5% of all gynecologic tumors.
  • Due to similarity of the clinical presentation the staging and therapeutic management have been adapted to that of ovarian cancer.
  • We retrospectively evaluated all the 19 patients who had been diagnosed with primary carcinoma of the fallopian tube at the Department of Obstetrics and Gynecology of the University of Zurich between 1977 and 1998.
  • At the time of diagnosis the median age was 62 (46-87) years.
  • Histology showed serous-papillary carcinoma, in ten (53%) cases.
  • Ovarian cancer and primary carcinoma of the fallopian tube are similar in many aspects.
  • Both carcinomas have a similar age distribution, show an increase among nulliparous women, are often of serous papillary histology, have a poor prognosis with stage and residual tumor size as important prognostic factors, and respond initially well to platinum-based chemotherapy.
  • Nevertheless, there appears to be a difference between the two diseases: primary carcinoma of the fallopian tube is more often diagnosed in an earlier stage.
  • [MeSH-major] Cystadenocarcinoma, Papillary / diagnosis. Fallopian Tube Neoplasms / diagnosis
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Analysis. Switzerland / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11214613.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 38
  •  go-up   go-down


13. Płoszyński A, Grzybowski W, Wojtylak S, Adamcio-Deptulska M, Mielnik J: [Primary carcinoma of the fallopian tube: a clinicopathological study of 11 cases]. Ginekol Pol; 2000 Sep;71(9):1184-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary carcinoma of the fallopian tube: a clinicopathological study of 11 cases].
  • OBJECTIVES: Clinicopathological study of eleven cases of carcinoma of the fallopian tube to understanding possible risk factors for therapeutic failure.
  • DESIGN: The study group consisted of 11 cases of primary carcinoma of the fallopian tube treated in our Department over 25-year period.
  • In all patients the diagnosis was established at the time of laparotomy.
  • The tumor was unilateral in 72.7% of the cases with equal frequency in the left or the right tube.
  • The tube was significantly dilated in nine patients, in two other the tumor was smaller then 10 mm.
  • Histologically the vast majority of the tumors was papillary serous adenocarcinoma, and only in one case clarocellulare adenocarcinoma was found.
  • All of the patients received postoperative adjuvant therapy: irradiation and or chemotherapy.
  • The mean interval from diagnosis to death was 44.5 months.
  • CONCLUSIONS: Multicenter studies are needed to improve the understanding of possible risk factors for diagnostic additionally therapeutic failure and the optimal treatment for each stage of the disease should be defined.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Fallopian Tube Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11083000.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


14. Osmanağaoğlu MA, Bozkaya H, Cobanoğlu U: Primary adenocarcinoma of the fallopian tube: a case report. Eur J Gynaecol Oncol; 2004;25(6):755-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary adenocarcinoma of the fallopian tube: a case report.
  • We report a case of a 75-year-old postmenopausal woman with primary fallopian tube carcinoma confined to the left fallopian tube in Stage IA-2, who is alive without evidence of disease three years after total abdominal hysterectomy, bilateral salpingo-oophorectomy, total omentectomy, pelvic and paraaortic lymph node dissection were performed.
  • Histopathological examination revealed a poorly differentiated (grade 3) papillary serous adenocarcinoma of the left fallopian tube.
  • Primary fallopian cancer should be suspected by clinicians even if the presenting symptoms are atypical and the primary treatment remains surgical resection followed by adjuvant chemotherapy or radiation.
  • Appropriate therapy for each stage of the disease should be defined and new studies are needed to better depict the clinical course and prognostic factors.
  • [MeSH-major] Adenocarcinoma / diagnosis. Fallopian Tube Neoplasms / diagnosis
  • [MeSH-minor] Aged. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15597861.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


15. Kelly MG, O'Malley D, Hui P, McAlpine J, Dziura J, Rutherford TJ, Azodi M, Chambers SK, Schwartz PE: Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation. Gynecol Oncol; 2004 Dec;95(3):469-73
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation.
  • OBJECTIVE: The coexistence of minimal uterine disease and extrauterine metastases is common in patients with uterine papillary serous carcinoma (UPSC).
  • The purpose of this study was to evaluate different therapeutic options in surgically staged patients.
  • Additionally, 11 of these 51 patients (21%) were diagnosed with two cancers: a stage IA UPSC and concomitant advanced stage serous cancer of the ovary, fallopian tube, or peritoneum.
  • Stage IA patients with no cancer in the hysterectomy specimen (defined as no residual uterine disease) had no recurrences (n = 10) regardless of treatment.
  • There was a trend toward increased survival in stage IA patients with residual uterine disease who were treated with chemoradiation (concomitant vaginal brachytherapy and platinum-based chemotherapy).
  • All patients with advanced stage UPSC (stage IIIC or IV or two primary cancers) did poorly regardless of treatment.
  • More effective treatment needs to be identified for advanced stage UPSC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cystadenocarcinoma, Papillary / therapy. Cystadenocarcinoma, Serous / therapy. Uterine Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Brachytherapy. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Female. Humans. Hysterectomy. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15581948.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin
  •  go-up   go-down


16. Brown JV 3rd, Micha JP, Rettenmaier MA, Abaid LN, Lopez KL, Goldstein BH: A pilot study evaluating a novel regimen comprised of carboplatin, paclitaxel, and bevacizumab for advanced-stage ovarian carcinoma. Int J Gynecol Cancer; 2010 Oct;20(7):1132-6
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot study evaluating a novel regimen comprised of carboplatin, paclitaxel, and bevacizumab for advanced-stage ovarian carcinoma.
  • OBJECTIVES: The purpose of this study was to assess the toxicity, progression-free survival, and response rate of advanced stage ovarian carcinoma patients treated with a novel regimen comprising paclitaxel, carboplatin, and bevacizumab.
  • RESULTS: Twenty patients received a combined total of 102 cycles of primary induction chemotherapy (median, 6; range, 2-6) and were evaluable for toxicity assessment.
  • Moreover, one patient developed a colorectal fistula and was subsequently removed from the study.
  • CONCLUSIONS: The tolerable hematologic toxicity and reasonable response rate after paclitaxel, carboplatin, and bevacizumab suggest that this regimen has moderate activity and can be safely administered to an advanced-stage ovarian carcinoma population.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Papillary / drug therapy. Cystadenocarcinoma, Serous / drug therapy. Fallopian Tube Neoplasms / drug therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Carboplatin / administration & dosage. Female. Humans. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Pilot Projects. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21495214.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


17. Matulonis U, Campos S, Duska L, Fuller A, Berkowitz R, Gore S, Roche M, Colella T, Lee H, Seiden MV, Gynecologic Oncology Research Program at Dana Farber/Partners Cancer Care, Dana Farber-Harvard Cancer Care: A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies. Gynecol Oncol; 2003 Nov;91(2):293-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies.
  • OBJECTIVES: In an effort to improve the results of primary chemotherapy for müllerian malignancies a novel chemotherapy program was piloted that delivered three sequential chemotherapy doublets.
  • After therapy, all women were clinically staged and evaluated by second-look laparoscopy/laparotomy (SLO) if clinical staging was negative for residual disease.
  • Forty-four women had either ovarian cancer or primary peritoneal carcinoma with 3 women diagnosed with fallopian tube carcinoma and 2 with papillary serous carcinoma of the uterus.
  • Thirty-nine of 49 (80%) patients completed therapy.
  • A total of 283 cycles of chemotherapy were delivered with acceptable toxicities.
  • Thirty-nine women completed all cycles of treatment.
  • CONCLUSIONS: Treatment with this sequential doublet regimen is feasible with a 38% pathologic CR rate.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Deoxycytidine / analogs & derivatives. Genital Neoplasms, Female / drug therapy. Mixed Tumor, Mullerian / drug therapy
  • [MeSH-minor] Carboplatin / administration & dosage. Carboplatin / adverse effects. Combined Modality Therapy. Cystadenocarcinoma, Papillary / drug therapy. Cystadenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Papillary / surgery. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / surgery. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Drug Administration Schedule. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / pathology. Endometrial Neoplasms / surgery. Fallopian Tube Neoplasms / drug therapy. Fallopian Tube Neoplasms / pathology. Fallopian Tube Neoplasms / surgery. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Middle Aged. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / surgery. Topotecan / administration & dosage. Topotecan / adverse effects

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14599858.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 7M7YKX2N15 / Topotecan; 80168379AG / Doxorubicin; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


18. Garcia AA, Bookman MA, Rodriguez-Rodriguez L, Mutch DG, Look KY, Gynecologic Oncology Group: Phase I escalation of gemcitabine combined with protracted oral etoposide in gynecologic malignancies: A Gynecologic Oncology Group study. Invest New Drugs; 2002 Nov;20(4):383-7
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Eligible patients had recurrent epithelial ovarian cancer, primary papillary peritoneal, or fallopian tube carcinoma.
  • All had received prior platinum/paclitaxel-based chemotherapy and had adequate hepatic, renal and bone marrow function.
  • Of six patients initially enrolled, one was removed after three days with fever, ascites and decreased albumin believed not to be treatment related.
  • One of the first three patients developed dose limiting toxicity (DLT) manifested as grade 4 neutropenia.
  • Patients who are previously treated with platinum/paclitaxel-based chemotherapy may be at particular risk for toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Etoposide / administration & dosage. Genital Neoplasms, Female / drug therapy
  • [MeSH-minor] Administration, Oral. Aged. Drug Administration Schedule. Female. Humans. Middle Aged

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1996 Oct;63(1):89-93 [8898175.001]
  • [Cites] Br J Cancer. 1997;75(6):869-77 [9062409.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;31(5):350-6 [8431968.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):543-50 [10931453.001]
  • [Cites] Cancer Res. 1991 Nov 15;51(22):6110-7 [1718594.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3093-100 [10963637.001]
  • [Cites] J Clin Oncol. 1994 Jan;12(1):60-3 [8270985.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3345-52 [9779711.001]
  • [Cites] N Engl J Med. 1996 Jan 4;334(1):1-6 [7494563.001]
  • [Cites] Ann Oncol. 1993 Jun;4(6):517-9 [8353095.001]
  • [Cites] Cancer Res. 1986 May;46(5):2566-71 [3697995.001]
  • [Cites] Eur J Cancer. 1998 Sep;34(10):1514-21 [9893622.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):405-10 [9469322.001]
  • [Cites] Cancer Chemother Pharmacol. 1994;34 Suppl:S69-75 [8070031.001]
  • [Cites] J Clin Oncol. 1991 Mar;9(3):389-93 [1999708.001]
  • [Cites] Biochem Pharmacol. 1999 Feb 15;57(4):407-15 [9933029.001]
  • [Cites] Cancer. 1986 May 1;57(9):1725-30 [3513943.001]
  • (PMID = 12448655.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6PLQ3CP4P3 / Etoposide; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


19. McCourt C, Dessie S, Bradley AM, Schwartz J, Brard L, Dizon DS: Is there a taxane-free interval that predicts response to taxanes as a later-line treatment of recurrent ovarian or primary peritoneal cancer? Int J Gynecol Cancer; 2009 Apr;19(3):343-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there a taxane-free interval that predicts response to taxanes as a later-line treatment of recurrent ovarian or primary peritoneal cancer?
  • OBJECTIVES: Taxanes have reported response rates of 20% to 40% in recurrent ovarian cancer (ROC) but are less well studied as a later-line treatment.
  • We reviewed our experience with taxanes in ROC to determine (1) if a taxane-free interval is associated with response rates in women with ROC and (2) if the use of intervening therapy (IT) affects subsequent response rates to taxanes.
  • METHODS: We retrospectively identified women who received first- or second-line platinum-taxane therapy and later received a single-agent taxane.
  • CONCLUSIONS: Taxanes maintain an activity as a later-line agent, even with 3 or more intervening therapies.
  • [MeSH-major] Fallopian Tube Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy. Taxoids / therapeutic use
  • [MeSH-minor] Adult. Aged. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / secondary. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / secondary. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / secondary. Female. Follow-Up Studies. Humans. Middle Aged. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19407557.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids
  •  go-up   go-down






Advertisement